Valeritas (NSDQ:VLRX) topped sales and earnings expectations on Wall Street this week with its second-quarter financial results.
The Bridgewater, N.J.-based company posted a net loss of -$10.9 million on sales of $6.5 million for the three months ended June 30, for sales growth of 36% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas tops sales, earnings estimates in Q2 appeared first on MassDevice.